Generics CEOs Unplug At AAM Conference

Four US Leaders Dive Deep On PBMs, Pricing, Biosimilars And Shortages

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

The AAM’s annual Access! 2024 conference brought its much-enjoyed CEOs Unplugged panel to Tampa again for another engaging discussion on critical issues, challenges and opportunities for generics and biosimilars in the US.

CEOs Unplugged panel
• Source: AAM

The 80-minute ‘CEOs Unplugged’ roundtable was introduced by the Association for Accessible Medicines’ interim CEO David Gaugh as – typically – the most anticipated event at the AAM’s two-day annual conference. So it showed, as seats filled quickly and other attendees stood or leaned at the back of the large conference hall in Tampa, eager to hear from the gathered panel of four esteemed US leaders, each boasting decades of experience across a wide range of backgrounds and geographies.

Regular attendee Allan Oberman, the CEO of Canadian giant Apotex, brought his 20-plus years of experience to the panel. Ten...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Manufacturing Focus

Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

 
• By Eliza Slawther

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.  

How Cellino’s Cassette Technology Will Impact Regenerative Medicine

 
• By Janelle Hart

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Agnė Vaitkevičienė: The Versatile CEO Driving Memel Biotech

 
• By Andrew Warmington

Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.   

China VBP, Localization And Other Strategies - How Far And Which Way?

 
• By Brian Yang

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting